Heart Failure

A new study reveals that noninvasive LVEDP screening can enhance heart failure detection and improve patient outcomes in primary care settings.

Your daily dose of the clinical news you may have missed.

FDA approval based on FINEARTS-HF trial showing 16% risk reduction in CV death and HF events.

Persistent hyperglycemia between ages 17 and 24 tripled the risk of left ventricular hypertrophy and did so 5 times faster among young women, a new study found.

Semaglutide 2.4 mg significantly lowered the risk of MACE and mortality in patients with ASCVD and overweight or obesity but without diabetes, researchers reported.

The risks to women's CV health differ, often significantly, from those faced by men, as demonstrated by 5 abstracts from the American College of Cardiology 2025 annual meeting.

Cannabis users had a more than sixfold increased risk of MI compared to non-users, according to a new study.

ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.

Finerenone treatment achieved a statistically significant reduction in a composite endpoint of CV death and HF events in a population not limited to CKD in T2D, Bayer announced.

Tirzepatide reduced the risk of severe heart failure outcomes by 38% and drove weight loss of 15.7% in adults with HFpEF and obesity, with and without T2D..